Skip to main content
Equibles
DBVT logo

DBVT · DBV Technologies S.A. · Metrics

Track DBVT — free

Use DBVT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DBVT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.94 -0.17 (-1.68%) At close · Nov 4 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Oct 28, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our management concluded that our recurring losses from operations, existing unrestricted cash, and cash equivalents raise substantial doubt about our ability to continue as a going concern for the next twelve months after issuance of our financial statements included in this Quarterly Report on Form 10-Q.”
View the 10-Q filed Oct 28, 2026
Market Cap
$624.64M
Shares
62.84M
Volume · Nov 4 378.31K Avg daily vol (3M) 368.25K

DBVT metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.94
Market cap
$624.64M

Price action

20 metrics
Price change (1W)
-0.1%
Price change (30D)
-3.2%
Price change (3M)
-26.3%
Price change (6M)
-48.1%
Price change (YTD)
-47.3%
Price change (1Y)
-29.1%
Trailing year
Price change (5Y)
—
52-week high
$24.54
52-week low
$8.87
Change from 52-week high
-58.8%
Change from 52-week low
+14.0%
Annualized volatility
71.2%
Annualized volatility (3M)
59.1%
Beta
0.8
RSI (14D)
48.8
Price vs SMA 50
-10.8%
Price vs SMA 200
-40.0%
Avg volume (3M)
367,512
Relative volume
0.9
Average dollar volume
$4.24M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
62.84M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
125.8×
reciprocal yield 0.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
170.1×
reciprocal yield 0.6%
P / book
4.3
reciprocal yield 23.4%
FCF yield
-30.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-32.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-28

Profitability

9 metrics
Gross margin
—
Operating margin
-5,577.0%
Trailing 12 months
Net margin
-5,547.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$208.36M
Net income (TTM)
−$207.25M
Trailing 12 months
Diluted EPS (TTM)
$-3.05
FCF margin
-5,131.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.33

Growth

11 metrics
Revenue growth YoY
-42.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.74M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+229.7%
Year over year · more shares
Revenue CAGR (3Y)
+5.2%
Revenue CAGR (5Y)
-13.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-139.5%
Return on assets
-96.2%
Debt / equity
0.0
Current ratio
3.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$191.71M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$165.50M
Latest balance sheet
Cash & equivalents
$165.70M
Total assets
$215.40M
Total debt
$200,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$188.38M
Capital expenditures (TTM)
$3.33M
R&D (TTM)
$144.48M
SG&A (TTM)
—
Stock compensation (TTM)
$12.79M
R&D / revenue
3,867.3%
Stock compensation / revenue
342.3%

Ownership (13F)

9 metrics
13F filers
80
13F filer change QoQ
+6
Institutional ownership
34.3%
Conviction holders (share of 13F filers)
1.3%
Crowding (high-turnover and private-fund holders)
3.9%
Private-fund adviser ownership
3.5%
Active holders' share change QoQ
-2.0%
Holder tenure
6.3
Price vs estimated holder cost
-6.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 2.0 days to cover
Days to cover
2.0d
Short-squeeze score
39 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1613780 CUSIP 23306J309 13F (30d) 13 filings 11 filers Visit website Investor relations